Suppr超能文献

慕尼黑经动脉化疗栓塞评分较 9 种已建立的肝癌分期系统的 TACE 改良版具有更高的预后能力。

The Munich-Transarterial Chemoembolisation Score Holds Superior Prognostic Capacities Compared to TACE-Tailored Modifications of 9 Established Staging Systems for Hepatocellular Carcinoma.

机构信息

Department of Medicine II, Liver Center Munich, University Hospital, Munich, Germany,

Institute of Laboratory Medicine, University Hospital, Munich, Germany.

出版信息

Digestion. 2019;100(1):15-26. doi: 10.1159/000493136. Epub 2018 Oct 3.

Abstract

BACKGROUND/AIMS: The recently proposed Munich-transarterial chemoembolisation-score (M-TACE) was tailored to suit hepatocellular Carcinoma (HCC) patients evaluated for TACE. M-TACE outperformed the established HCC-staging-systems and successfully passed external validation. Modifications of staging-systems through the rearrangement of stages or by adding prognostic factors are methods of improving prognostic power. M-TACEs performance compared to scores modified this way should be tested.

METHODS

Seven well-known HCC staging-systems (including Cancer of the Liver Italian Program-score [CLIP] and Barcelona Clinic liver cancer [BCLC]) and 2 TACE-specific scores (Selection for Transarterial Chemoembolisation Treatment [STATE] and Hepatoma Arterial embolisation Prognostic [HAP]) were rearranged in a cohort of 186 TACE-patients through score-point-analysis and subsequent linking of non-significant adjacent score-points. Additionally, a new score was constructed by combining the top established staging-system in TACE patients (CLIP-TACE) and the prognostic parameter with the highest hazard ratio for death in the TACE-cohort [C-reactive protein (CRP)]. Additionally, the TACE-tailored-scores were applied to an external TACE-cohort (n = 71). -Results: Rearrangement resulted in optimal stratification and monotonicity. CLIP-TACE demonstrated the best prognostic capability of all rearranged scores (c-index 0.668, AIC 1294) and the addition of CRP yielded further prognostic improvement (c-index 0.680, AIC 1289). However, superiority over M-TACE could not be achieved by any of the new scores in the internal and external cohort.

CONCLUSION

M-TACE outperforms TACE-tailored modifications of all relevant HCC-staging-systems. Prospective validation of M-TACE to promote its role as the preferred staging-system for TACE-patients is therefore justified.

摘要

背景/目的:最近提出的慕尼黑经动脉化疗栓塞评分(M-TACE)是为适合接受 TACE 评估的肝细胞癌(HCC)患者量身定制的。M-TACE 优于现有的 HCC 分期系统,并成功通过了外部验证。通过重新排列分期或添加预后因素来修改分期系统是提高预后能力的方法。应测试 M-TACE 与以这种方式修改的评分相比的性能。

方法

通过评分点分析和随后链接非显著相邻评分点,将七种著名的 HCC 分期系统(包括癌症肝脏意大利计划评分[CLIP]和巴塞罗那临床肝癌[BCLC])和两种 TACE 特异性评分(选择经动脉化疗栓塞治疗[STATE]和肝癌动脉栓塞预后[HAP])重新排列在 186 名 TACE 患者的队列中。此外,通过结合 TACE 患者中最佳的既定分期系统(CLIP-TACE)和 TACE 队列中死亡风险最高的预后参数(C 反应蛋白[CRP])构建了一个新的评分。此外,将 TACE 量身定制的评分应用于外部 TACE 队列(n=71)。-结果:重新排列导致最佳分层和单调性。CLIP-TACE 在所有重新排列的评分中显示出最佳的预后能力(c 指数 0.668,AIC 1294),并且添加 CRP 可进一步提高预后(c 指数 0.680,AIC 1289)。然而,在内部和外部队列中,任何新评分都无法超越 M-TACE。

结论

M-TACE 优于所有相关 HCC 分期系统的 TACE 量身定制修改。因此,有理由对 M-TACE 进行前瞻性验证,以促进其作为 TACE 患者首选分期系统的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验